Swiss simvastatin multicenter study: 1. Efficacy of 10 mg simvastatin daily in patients with primary hypercholesterolemia
Riesen, W.F.; Keller, U.; Del Bufalo, A.; Reutter, F.W.; Baur, H.R.; Golay, A.; Bertel, O.; Kummer, H.; Kistler, H.; Ammann, F.
Schweizerische Medizinische Wochenschrift 119(48): 1719-1723
1989
ISSN/ISBN: 0036-7672 PMID: 2694363 Document Number: 334461
In a Swiss multicenter study with determination of lipid and lipoprotein parameters in a central laboratory, the efficacy of simvastatin, MSD, was evaluated in patients with primary hypercholesterolemia. Lipid and lipoprotein values were determined in 109 patients before and after 6 weeks' therapy with 10 mg simvastatin per day. A significant decrease in total cholesterol, LDL-cholesterol and apo B, of 21.1, 25.8 and 24.1% respectively, was observed. No influence of simvastatin on apo A-II was found, but HDL-cholesterol and apo A-I were slightly increased (+6.1 and 4.4% respectively). The data show that HMG-CoA reductase inhibitors constitute a new class of effective drugs for the treatment of hypercholesterolemia.